Prima's CVac improves OS in ovarian cancer trial

Prima BioMed (ASX:PRR) said its cancer treatment candidate CVac was able to demonstrate a statistically significant improvement in overall survival during a clinical trial in ovarian cancer.

The second remission patients receiving CVac in the CAN-003 trial have not yet reached a median overall survival after 36 months, the company said.

By comparison, the standard of care cohort demonstrated a median overall survival of 25.53 months, suggesting at least a 10-month median advantage using CVac.

The data align with earlier details of the effect on overall survival during the trial, as released in June.

No median has yet been reached for first remission patients in either cohort, but the data so far indicates a slightly positive trend in CVac patients, Prima said.

Prima CEO Marc Voight said CVac’s performance in the second remission cohort has been effective enough that the company no longer expects to be able to complete a final analysis of the trial data by the end of the year.

“This data is extremely encouraging and further supports the overall survival trend we presented earlier this year for second remission patients,” he said. “We will continue to monitor the second remission CAN-003 patients and look forward to updating the market on their progress.”

Prima BioMed (ASX:PRR) shares were trading 2.5% higher at $0.041 as of around 1.30 pm on Thursday.